GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at TD Cowen from $14.00 to $24.00. They now have a "buy" rating on the stock.
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $15.00 to $19.00. They now have a "buy" rating on the stock.
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
GeneDx Holdings Corp. (NASDAQ: WGS) had its price target raised by analysts at BTIG Research from $11.00 to $15.00. They now have a "buy" rating on the stock.